{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:05:47Z","timestamp":1778637947082,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"New Energy and Industrial Technology Development Organization","award":["P07022"],"award-info":[{"award-number":["P07022"]}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1002\/jps.24499","type":"journal-article","created":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T16:51:44Z","timestamp":1433350304000},"page":"3154-3161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development"],"prefix":"10.1016","volume":"104","author":[{"given":"Shinji","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Suzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Inano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuninori","family":"Mutaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.24499_bb0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1002\/jps.24499_bb0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"11 June 2009","key":"10.1002\/jps.24499_bb0015","article-title":"Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals","author":"Harmonised Tripartite Guideline","year":"2009","journal-title":"Dated"},{"key":"10.1002\/jps.24499_bb0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clpt.2006.05.008","article-title":"Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs","volume":"80","author":"Lappin","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.24499_bb0025","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1517\/17425250802531767","article-title":"The utility of microdosing over the past 5years","volume":"4","author":"Lappin","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"10.1002\/jps.24499_bb0030","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.addr.2010.09.010","article-title":"Impact of microdosing clinical study\u2014Why necessary and how useful?","volume":"63","author":"Sugiyama","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.24499_bb0035","first-page":"66","article-title":"Drug metabolism and pharmacokinetics in drug discovery","volume":"6","author":"Roberts","year":"2003","journal-title":"Curr Opin Drug Discov Dev"},{"key":"10.1002\/jps.24499_bb0040","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1124\/dmd.105.004143","article-title":"A novel model for prediction of human drug clearance by allometric scaling","volume":"33","author":"Tang","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.24499_bb0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2885.2006.00786.x","article-title":"Interspecies allometric scaling. Part I: Prediction of clearance in large animals","volume":"29","author":"Mahmood","year":"2006","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1002\/jps.24499_bb0050","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1002\/jps.21708","article-title":"The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans","volume":"98","author":"Takahashi","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24499_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-642-10324-7_2","article-title":"Species differences in pharmacokinetics and pharmacodynamics","volume":"199","author":"Toutain","year":"2010","journal-title":"Handb Exp Pharmacol"},{"key":"10.1002\/jps.24499_bb0060","first-page":"179","article-title":"The absolute oral bioavailability of selected drugs","volume":"27","author":"Sietsema","year":"1989","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1002\/jps.24499_bb0065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejps.2013.08.018","article-title":"Animal versus human oral drug bioavailability: Do they correlate?","volume":"57","author":"Musther","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.24499_bb0070","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s11095-011-0423-8","article-title":"Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies","volume":"28","author":"Yamane","year":"2011","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24499_bb0075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/clpt.2011.142","article-title":"Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study","volume":"90","author":"Maeda","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.24499_bb0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-198611060-00002","article-title":"Clinical pharmacokinetics of verapamil, nifedipine and diltiazem","volume":"11","author":"Echizen","year":"1986","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1002\/jps.24499_bb0085","first-page":"23S","article-title":"The metabolism and pharmacokinetics of nicardipine hydrochloride in man","volume":"20","author":"Graham","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/jps.24499_bb0090","series-title":"Guidance for industry. Bioanalytical method validation","article-title":"Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM)","author":"U.S. Department of Health and Human Services","year":"2001"},{"key":"10.1002\/jps.24499_bb0095","first-page":"972","article-title":"Pharmacokinetic model of diltiazem","volume":"33","author":"K\u00f6lle","year":"1983","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/jps.24499_bb0100","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1517\/17425255.2013.786042","article-title":"Microdosing and drug development: Past, present and future","volume":"9","author":"Lappin","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1002\/jps.24499_bb0105","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0090-9556(25)08415-6","article-title":"The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism","volume":"24","author":"Holtbecker","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.24499_bb0110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s002280000235","article-title":"Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: Evidence for dominant presystemic elimination at the gut site","volume":"56","author":"Uno","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.24499_bb0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00228-002-0516-8","article-title":"Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers","volume":"58","author":"Christensen","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"issue":"4Pt 2","key":"10.1002\/jps.24499_bb0120","first-page":"II18","article-title":"Pharmacokinetics and metabolism of nifedipine","volume":"5","author":"Raemsch","year":"1983","journal-title":"Hypertension"},{"key":"10.1002\/jps.24499_bb0125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00610053","article-title":"Pharmacokinetics of diltiazem after intravenous and oral administration","volume":"24","author":"Hermann","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.24499_bb0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/00498258009033779","article-title":"Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species","volume":"10","author":"Higuchi","year":"1980","journal-title":"Xenobiotic"},{"key":"10.1002\/jps.24499_bb0135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/bdd.2510080205","article-title":"Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects","volume":"8","author":"Wagner","year":"1987","journal-title":"Biopharm Drug Dispos"},{"key":"10.1002\/jps.24499_bb0140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s002280050292","article-title":"Pharmacokinetics of nicardipine enantiomers in healthy young volunteers","volume":"52","author":"Inotsume","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.24499_bb0145","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01716446","article-title":"Pharmacokinetics and absolute bioavailability of diltiazem in humans","volume":"62","author":"Ochs","year":"1984","journal-title":"Klin Wochenschr"},{"key":"10.1002\/jps.24499_bb0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02389.x","article-title":"Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract","volume":"60","author":"Thorn","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/jps.24499_bb0155","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","article-title":"Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens","volume":"75","author":"Richter","year":"2004","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916300958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916300958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:24:56Z","timestamp":1758360296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916300958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0022354916300958"],"URL":"https:\/\/doi.org\/10.1002\/jps.24499","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/jps.24499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Wiley Periodicals, Inc. and the American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}